PURPOSE: Understanding the effect of genes on progression to different stages of age-related macular degeneration (AMD) may suggest stage-specific therapeutic targets and more precise prediction of the development of this disease. METHODS: Progression events and time to each stage of AMD were derived from the longitudinal data of 2560 subjects without advanced AMD. SNPs in 12 AMD risk loci were genotyped. A multistate Markov model for progression from normal to intermediate drusen, then to large drusen, and eventually to neovascular disease (NV) or geographic atrophy (GA) was applied to estimate stage-specific hazard ratios for each SNP. The effects of these genetic factors were also estimated by a multivariate multistate Markov model adjusted for baseline age, sex, smoking, body mass index (BMI), education, antioxidant treatment, and the status of AMD in the fellow eye. RESULTS: Controlling for demographic and behavioral factors and other SNPs, the TT genotype of rs10468017 in LIPC was associated with decreased risk of progression from large drusen to NV (HR = 0.57, P = 0.04) and tended to reduce the risk of progression from normal to intermediate drusen (HR = 0.72, P = 0.07). The SNP rs1883025 (T allele) in ABCA1 was associated with decreased risk of progression from normal to intermediate drusen (HR per allele = 0.82 per allele, P = 9.7 × 10(-3)) and from intermediate drusen to large drusen (HR per allele = 0.77, P = 5.2 × 10(-3)). The genes CFH, C3, CFB, and ARMS2/HTRA1 were associated with progression from intermediate drusen to large drusen and from large drusen to GA or NV. CONCLUSIONS: Genes in different pathways influence progression to different stages of AMD.
PURPOSE: Understanding the effect of genes on progression to different stages of age-related macular degeneration (AMD) may suggest stage-specific therapeutic targets and more precise prediction of the development of this disease. METHODS: Progression events and time to each stage of AMD were derived from the longitudinal data of 2560 subjects without advanced AMD. SNPs in 12 AMD risk loci were genotyped. A multistate Markov model for progression from normal to intermediate drusen, then to large drusen, and eventually to neovascular disease (NV) or geographic atrophy (GA) was applied to estimate stage-specific hazard ratios for each SNP. The effects of these genetic factors were also estimated by a multivariate multistate Markov model adjusted for baseline age, sex, smoking, body mass index (BMI), education, antioxidant treatment, and the status of AMD in the fellow eye. RESULTS: Controlling for demographic and behavioral factors and other SNPs, the TT genotype of rs10468017 in LIPC was associated with decreased risk of progression from large drusen to NV (HR = 0.57, P = 0.04) and tended to reduce the risk of progression from normal to intermediate drusen (HR = 0.72, P = 0.07). The SNP rs1883025 (T allele) in ABCA1 was associated with decreased risk of progression from normal to intermediate drusen (HR per allele = 0.82 per allele, P = 9.7 × 10(-3)) and from intermediate drusen to large drusen (HR per allele = 0.77, P = 5.2 × 10(-3)). The genes CFH, C3, CFB, and ARMS2/HTRA1 were associated with progression from intermediate drusen to large drusen and from large drusen to GA or NV. CONCLUSIONS: Genes in different pathways influence progression to different stages of AMD.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Julian Maller; Sarah George; Shaun Purcell; Jes Fagerness; David Altshuler; Mark J Daly; Johanna M Seddon Journal: Nat Genet Date: 2006-08-27 Impact factor: 38.330
Authors: Mingyao Li; Pelin Atmaca-Sonmez; Mohammad Othman; Kari E H Branham; Ritu Khanna; Michael S Wade; Yun Li; Liming Liang; Sepideh Zareparsi; Anand Swaroop; Gonçalo R Abecasis Journal: Nat Genet Date: 2006-08-27 Impact factor: 38.330
Authors: Andrew Dewan; Mugen Liu; Stephen Hartman; Samuel Shao-Min Zhang; David T L Liu; Connie Zhao; Pancy O S Tam; Wai Man Chan; Dennis S C Lam; Michael Snyder; Colin Barnstable; Chi Pui Pang; Josephine Hoh Journal: Science Date: 2006-10-19 Impact factor: 47.728
Authors: Andrea Rivera; Sheila A Fisher; Lars G Fritsche; Claudia N Keilhauer; Peter Lichtner; Thomas Meitinger; Bernhard H F Weber Journal: Hum Mol Genet Date: 2005-09-20 Impact factor: 6.150
Authors: Zhenglin Yang; Nicola J Camp; Hui Sun; Zongzhong Tong; Daniel Gibbs; D Joshua Cameron; Haoyu Chen; Yu Zhao; Erik Pearson; Xi Li; Jeremy Chien; Andrew Dewan; Jennifer Harmon; Paul S Bernstein; Viji Shridhar; Norman A Zabriskie; Josephine Hoh; Kimberly Howes; Kang Zhang Journal: Science Date: 2006-10-19 Impact factor: 47.728
Authors: John R W Yates; Tiina Sepp; Baljinder K Matharu; Jane C Khan; Deborah A Thurlby; Humma Shahid; David G Clayton; Caroline Hayward; Joanne Morgan; Alan F Wright; Ana Maria Armbrecht; Baljean Dhillon; Ian J Deary; Elizabeth Redmond; Alan C Bird; Anthony T Moore Journal: N Engl J Med Date: 2007-07-18 Impact factor: 91.245
Authors: Gabriëlle H S Buitendijk; Elena Rochtchina; Chelsea Myers; Cornelia M van Duijn; Kristine E Lee; Barbara E K Klein; Stacy M Meuer; Paulus T V M de Jong; Elizabeth G Holliday; Ava G Tan; André G Uitterlinden; Theru S Sivakumaran; John Attia; Albert Hofman; Paul Mitchell; Johannes R Vingerling; Sudha K Iyengar; A Cecile J W Janssens; Jie Jin Wang; Ronald Klein; Caroline C W Klaver Journal: Ophthalmology Date: 2013-10-10 Impact factor: 12.079
Authors: Yi Yu; Erin K Wagner; Eric H Souied; Sanna Seitsonen; Ilkka J Immonen; Paavo Häppölä; Soumya Raychaudhuri; Mark J Daly; Johanna M Seddon Journal: Hum Mol Genet Date: 2016-12-01 Impact factor: 6.150
Authors: Ronald Klein; Chelsea E Myers; Stacy M Meuer; Ronald E Gangnon; Theru A Sivakumaran; Sudha K Iyengar; Kristine E Lee; Barbara E K Klein Journal: JAMA Ophthalmol Date: 2013-03 Impact factor: 7.389
Authors: Lorah T Perlee; Aruna T Bansal; Karen Gehrs; Jeffrey S Heier; Karl Csaky; Rando Allikmets; Paul Oeth; Toni Paladino; Daniel H Farkas; P Lyle Rawlings; Gregory S Hageman Journal: Ophthalmology Date: 2013-03-21 Impact factor: 12.079